Abstract B185: TPX-0005, a supreme ROS1 inhibitor, overcomes crizotinib-resistant ROS1 mutations including solvent front mutation G2032R and gatekeeper mutation L2026M
2018
The fusion kinases of
ROS1and ALK have been identified as oncogene drivers in small portions of many malignancies, especially in non-small cell lung cancer (NSCLC). ALK/
ROS1/MET inhibitor
crizotinibhas been approved by the US Food and Drug Administration for the treatment of ALK or
ROS1-positive non-small cell lung cancer in 2011 and 2016, respectively. The emergence of drug resistance presents a major issue for targeted therapy. Although
ceritinib,
alectinib, and
brigatinibhave been approved for
crizotinib-refractory ALK + patients with NSCLC, treatment options for patients with
ROS1+ NSCLC are limited, especially for
crizotinib-refractory patients.
Ceritiniband entectinib demonstrated clinical efficacy only in
crizotinib-naive
ROS1+ patients. The most common resistance mechanisms to
crizotinibtreatment in
ROS1+ NSCLC is the solvent front mutation
ROS1G2032R and
gatekeepermutation
ROS1L2026M. TPX-0005, a novel three-dimensional macrocycle with a much smaller size than current
ROS1inhibitors in the clinic, was designed to overcome clinical
resistance mutationssystematically. TPX-0005 potently inhibited both wild type and mutant
ROS1sincluding solvent front mutations and
gatekeepermutations. TPX-0005 showed pico-molar activity against
ROS1kinase (IC 50 0.076 nM) in Reaction Biology kinase assay. The comparison of TPX-0005 with other
ROS1inhibitors in Ba/F3 cell proliferation assays is presented in the table. In the xenograft tumor model studies, TPX-0005 dramatically caused tumor regression in the tumors carrying WT or solvent-front mutated
ROS1
fusion gene. Overall, TPX-0005 demonstrated desired drug-like properties, good safety profile, and is a supreme
ROS1inhibitor against WT and various mutated
ROS1s. A phase 1/2 clinical trial of TPX-0005 is actively being pursued (NCT03093116). ND: not determined. Citation Format: J. Jean Cui, Dayong Zhai, Wei Deng, Evan Rogers, Zhongdong Huang, Jeffrey Whitten, John Lim, Yishan Li. TPX-0005, a supreme
ROS1inhibitor, overcomes
crizotinib-resistant
ROS1mutations including solvent front mutation G2032R and
gatekeepermutation L2026M [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B185.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI